

DAFTAR PUSTAKA

- Abdulkareem, I. dan Blair, M. 2013. Phosphatase and tensin homologue deleted on chromosome 10. *Nigerian Medical Journal*, 54(2), p.79.
- Abidin, Z. 2018. Peran Jalur Phosphatidyl-Inositol-3-kinase (PI3K) dalam Resistensi Kemoterapi pada Kanker. *Qanun Medika-Medical Journal Faculty of Medicine Muhammadiyah Surabaya*, 2(01).
- Ahmadi, A., Najafi, M., Farhood, B. and Mortezaee, K., 2019. Transforming growth factor- β signaling: tumorigenesis and targeting for cancer therapy. *Journal of cellular physiology*, 234(8), pp.12173-12187.
- Amirudin, R. 2014, 'Fisiologi dan Biokimia Hati', in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid II*. Edisi VI. Jakarta: Interna Publishing.
- Ambros V. 2013. Victor Ambros: the broad scope of microRNAs. Interview by Caitlin Sedwick. *J Cell Biol*, 13;201(4):492-3.
- Anggraini, D. 2019. Laboratory Examination in Hepatocellular Carcinoma. *Health & Medical Journal*, 1(2), 50-53.
- Anwar, S.L. and Lehmann, U., 2014. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. *World journal of gastroenterology: WJG*, 20(24), p.7894.
- Anwar, S, L., Samuel, J, H., Teguh, A., dan Sofia, M, H., 2017. *Micro-RNA*. Yogyakarta: Universitas Gadjah Mada Press.
- Baek, H.J., Pishvaian, M.J., Tang, Y., Kim, T.H., Yang, S., Zouhairi, M.E., Mendelson, J., Shetty, K., Kallakury, B., Berry, D.L. and Shin, K.H., 2011. Transforming growth factor- β adaptor, β 2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. *Hepatology*, 53(5), pp.1676-1684.
- Bağırsakçı, E., Şahin, E., Atabey, N., Erdal, E., Guerra, V. and Carr, B.I., 2017. Role of albumin in growth inhibition in hepatocellular carcinoma. *Oncology*, 93(2), pp.136-142.

- Battle, E. and Massagué, J., 2019. Transforming growth factor- β signaling in immunity and cancer. *Immunity*, 50(4), pp.924-940.
- Bracht, J. W. P., Mayo-de-las-Casas, C., Berenguer, J., Karachaliou, N., & Rosell, R. 2018. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. *Current Oncology Reports*, 20(9), 70.
- Brady, C.W., 2015. Liver disease in menopause. *World Journal of Gastroenterology: WJG*, 21(25), p.7613.
- Brown, K. K., & Toker, A. 2015. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. *F1000prime reports*, 7.
- Budihusodo, U. 2014, 'Karsinoma Hati', in Setiati, S. et al. (eds) *Buku Ajar Ilmu Penyakit Dalam Jilid III*. Edisi VI. Jakarta: Interna Publishing.
- Chen, Z.; Ma, T.; Huang, C.; Hu, T.; Li, J. 2014. The Pivotal Role of microRNA-155 in the Control of Cancer. *J. Cell. Physiol.* 229:545–550.
- Choi, J.Y., Lee, J.M. and Sirlin, C.B., 2014. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. *Radiology*, 272(3), pp.635-654.
- Daniunaite, K., Dubikaityte, M., Gibas, P., Bakavicius, A., Rimantas Lazutka, J., Ulys, A., Jankevicius, F. and Jarmalaite, S., 2017. Clinical significance of miRNA host gene promoter methylation in prostate cancer. *Human Molecular Genetics*, 26(13), pp.2451-2461.
- Das, K., Chan, X. B., Epstein, D., Teh, B. T., Kim, K. M., Kim, S. T. & Tan, P. 2016. NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. *ESMO open*, 1(1).
- De Miguel Pérez, D., Martínez, A.R., Palomo, A.O., Ureña, M.D., Puche, J.L.G., Remacho, A.R., Hernandez, J.E., Acosta, J.A.L., Sánchez, F.G.O. and Serrano, M.J., 2020. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. *Scientific reports*, 10(1), pp.1-13.

- Dhanasekaran, R., Bando, S., & Roberts, L. R. 2016. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000 Faculty*. <http://doi.org/10.12688/f1000research.6946.1>.
- Dilsiz, N. (2020). Role of exosomes and exosomal microRNAs in cancer. *Future science OA*, 6(4).
- Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. (2019). Role of liver biopsy in hepatocellular carcinoma. *World J Gastroenterol*. 25(40): 6041-6052.
- Edgar JR (2016). Q&A: What are exosomes, exactly? *BMC Biology* 14:46 <https://doi.org/10.1186/s12915-016-0268-z>.
- European Association For The Study Of The Liver. (2018). EASL clinical practice guidelines: management of hepatocellular carcinoma. *Journal of hepatology*, 69(1), 182-236.
- Fu, X., Wen, H., Jing, L., Yang, Y., Wang, W., Liang, X., & Tian, T. 2017. Micro RNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI 3K/Akt pathway. *Cancer science*, 108(4), 620-631.
- Galun, D., Basaric, D., Zuvella, M., Bulajic, P., Bogdanovic, A., Bidzic, N., & Milicevic, M. 2015. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. *World Journal of Hepatology*. <http://doi.org/10.4254/wjh.v7.i20.2274>
- Gao, Y., Feng, B., Han, S., Zhang, K., Chen, J., Li, C., Wang, R., and Chen, L., 2016. The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment. *Cell Physiol Biochem*, (305): 427–448. Available at <http://dx.doi.org/10.1159/000438641>.
- Garcia-Tsao, G. and Bosch, J. 2010, 'Management of Varices and Variceal Hemorrhage in Cirrhosis', *New England Journal of Medicine*, 362(9), pp.823–832.
- Garzon, R., Fabbri, M., Cimmino, A., Calin, G.A., and Croce, C.M. 2006. MicroRNA expression and function in cancer. *Trends Mol Med*, 12(12): 580–587. Available at <http://dx.doi.org/10.1016/j.molmed.2006.10.006>.

- Giannelli, G., Rani, B., Dituri, F., Cao, Y. and Palasciano, G., 2014. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. *Gut*, 63(10), pp.1668-1676.
- GLOBOCAN. 2018. Cancer Today. <https://gco.iarc.fr/today>. Diakses pada tanggal 20 Februari 2019.
- Guan, C., Yang, F., He, X., Li, T., Yang, Q., He, H., & Xu, M. 2016. Clinical significance of microRNA-155 expression in hepatocellular carcinoma. *Oncology Letters*. 11(2), 1574-1580.
- Gutierrez, L.S., Suckow, M., Lawler, J., Ploplis, V.A. and Castellino, F.J., 2003. Thrombospondin 1—a regulator of adenoma growth and carcinoma progression in the APC Min/+ mouse model. *Carcinogenesis*, 24(2), pp.199-207.
- Hall, P. and Cash, J., 2012. What is the real function of the liver ‘function’ tests?. *The Ulster medical journal*, 81(1), p.30.
- Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. *cell*, 144(5), pp.646-674.
- He C, Zheng S, Luo Y, Wang B (2018). Exosome Theranostics: Biology and Translational Medicine. *Theranostics*. 8(1): 237–255.
- Heldin, C.H., Landström, M., & Moustakas, A., 2009, Mechanism of TGF- β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition, *Current Opinion in Cell Biology*, 21(2):166–176. <https://doi.org/10.1016/j.ceb.2009.01.021>.
- Huan, L., Liang, L.H. and He, X.H., 2016. Role of microRNAs in inflammation-associated liver cancer. *Cancer biology & medicine*, 13(4), p.407.
- Hulf, T., Sibbritt, T., Wiklund, E. D., Bert, S., Strbenac, D., Statham, A. L., et al. 2011. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. *BMC genomics*, 12(1), 54.
- Hunt, E. A., Broyles, D., Head, T., & Deo, S. K. 2015. MicroRNA detection: current technology and research strategies. *Annual review of analytical chemistry*, 8, 217-237.

- Jerde, T. J. 2015. Phosphatase and Tensin Homologue: Novel Regulation by Developmental Signaling. *Journal of Signal Transduction* pp.1-13.
- Karageorgos, S.A., Stratakou, S., Koulentaki, M., Voumvouraki A., Mantaka, A., Samonakis, D., Notas, G., Kouroumalis E. A.2017, 'Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study', *Annals of Gastroenterology*, 30(3), pp. 357- 363.
- Koduru, S.V., Leberfinger, A.N., Kawasawa, Y.I., Mahajan, M., Gusani, N.J., Sanyal, A.J. and Ravnich, D.J., 2018. Non-coding RNAs in various stages of liver disease leading to hepatocellular carcinoma: differential expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. *Scientific reports*, 8(1), pp.1-48.
- Kumar *et al.* 2007. *Robbin's Basic Pathology; 8th Edition*. London: Elsevier. Hal. 213-214.
- Kun Z, Chun FG, Yun PZ, Hai LL, et al. 2010. Simpler Score of Routine Laboratory Tests Predicts Liver Fibrosis in Patients with Chronic Hepatitis B. *Journal of Gastroenterology and Hepatology*. 96(4):1569-77
- Labгаа, I., Villanueva, A., Dormond, O., Demartines, N. and Melloul, E., 2021. The role of liquid biopsy in hepatocellular carcinoma prognostication. *Cancers*, 13(4), p.659.
- Lee, T.K.W., Cheung, V.C.H., Lu, P., Lau, E.Y.T., Ma, S., Tang, K.H., Tong, M., Lo, J. and Ng, I.O.L., 2014. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. *Hepatology*, 60(1), pp.179-191.
- Lee, Y. S., & Dutta, A. 2009. MicroRNAs in cancer. *Annual Review of Pathological Mechanical Disease*, 4, 199-227.
- Liao, W. W., Zhang, C., Liu, F. R., & Wang, W. J. 2018. Effects of miR-155 on proliferation and apoptosis by regulating FoxO3a/BIM in liver cancer cell line KHSLM3. *Eur Rev Med Pharmacol Sci*, 22(5), 1277-85.
- Li, D. P., Fan, J., Wu, Y. J., Xie, Y. F., Zha, J. M., & Zhou, X. M. 2017. MiR-155 up-regulated by TGF- β promotes epithelial-mesenchymal transition, invasion

- and metastasis of human hepatocellular carcinoma cells in vitro. *American journal of translational research*, 9(6), 2956.
- Li M, Ding X, He M, Cheung S. 2010. MicroRNA and cancer. *APPS J.* 12(3):309–17.
- Li, X., Li, C., Zhang, L., Wu, M., Cao, K., Jiang, F. & Li, W. 2020. The significance of exosomes in the development and treatment of hepatocellular carcinoma. *Molecular Cancer*, 19(1), 1.
- Liu, H.X., Fang, Y., Hu, Y., Gonzalez, F.J., Fang, J. and Wan, Y.J.Y., 2013. PPAR β regulates liver regeneration by modulating Akt and E2f signaling. *PloS one*, 8(6), p.e65644.
- Loh, H.Y., Norman, B.P., Lai, K.S., Rahman, N.M.A.N.A., Alitheen, N.B.M. and Osman, M.A., 2019. The regulatory role of microRNAs in breast cancer. *International journal of molecular sciences*, 20(19), p.4940.
- Lu, L.C., Hsu, C.H., Hsu, C. and Cheng, A.L., 2016. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges. *Liver cancer*, 5(2), pp.128-138.
- Lu, Z., Li, X., Xu, Y., Chen, M., Chen, W., Chen, T., Tang, Q. and He, Z., 2019. microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma. *Cell death & disease*, 10(10), pp.1-12.
- Lui, H. F. 2011. Screening for hepatocellular carcinoma. *International journal of hepatology*, 2011:4.
- Maclean, Kirsteen. 2019. *Applications with Exosomes and Extracellular Vesicles in miRNA Research*. NanoString Technologies, Inc. : USA
- Matsuura, Y., Wada, H., Eguchi, H., Gotoh, K., Kobayashi, S., Kinoshita, M., & Asaoka, T. 2019. Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells. *Digestive diseases and sciences*, 64(3), 792-802.
- Mittal, S. and El-Serag, H.B., 2013. Epidemiology of HCC: consider the population. *Journal of clinical gastroenterology*, 47, p.S2.
- Mohamed, A. A., Omar, A. A. A., EL-Awady, R. R., Hassan, S. M. A., Eitah, W. M. S., Ahmed, R., & Mohamed, A. A. 2020. MiR-155 and MiR-665 role as

- potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. *Journal of Translational Internal Medicine*, 8(1), 32-40.
- Montella, M., D'Arena, G., Crispo, A., Capunzo, M., Nocerino, F., Grimaldi, M., Barbieri, A., D'Ursi, A.M., Tecce, M.F., Amore, A. and Galdiero, M., 2015. Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma. *International Journal of Endocrinology*, 2015.
- Morishita, A., Oura, K., Tadokoro, T., Fujita, K., Tani, J. and Masaki, T., 2021. MicroRNAs in the pathogenesis of hepatocellular carcinoma: A review. *Cancers*, 13(3), p.514.
- Ning, S., Liu, H., Gao, B., Wei, W., Yang, A., Li, J. and Zhang, L., 2019. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. *Oncology letters*, 18(3), pp.3381-3387.
- Nik Mohamed Kamal NNSB and Shahidan WNS (2020) Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers?. *Front. Pharmacol.* 10:1500. <http://doi.org/10.3389/fphar.2019.01500>.
- Niu, L.J., Zhang, Y.M., Huang, T., Sun, X.F. and Luo, S.X., 2021. Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression. *Annals of Translational Medicine*, 9(2).
- Palma, G., Frasci, G., Chirico, A., Esposito, E., Siani, C., Saturnino, C. & D'Aiuto, M. 2015. Triple negative breast cancer: looking for the missing link between biology and treatments. *Oncotarget*, 6(29), 26560.
- Patasik YZ, Waleleng BJ, Wantania F. Profil pasien sirosis hati yang dirawat inap di RSUP Prof. Dr. D. Kandou Manado periode Agustus 2012-Agustus 2014. 2015. *Eclinic*. 3(1):342-7.
- Poon, R, T., Chung, K.K., Cheung, S, T., Cecilia, P, L., See, W, T., Ka, L, L., Wan, C, Y., George, P, T., and Sheung, T, F. 2004. Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma. *Clinical Cancer Research*, Vol. 10, 4150–4157

- Qi, P. dkk. 2009. "Serum Micro-RNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patiens with Chronic Hepatitis B Virus Infection". *PLoS ONE* 6, e28486.
- Rennie, W., Liu, C., Carmack, C. S., Wolenc, A., Kanoria, S., Lu, J., & Ding, Y. 2014. STarMir: a web server for prediction of microRNA binding sites. *Nucleic acids research*, 42(W1), W114-W118.
- Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K. and Schwarzenbach, H., 2010. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. *Breast Cancer Research*, 12(6), pp.1-8.
- Semela, D. and Dufour, J.F., 2004. Angiogenesis and hepatocellular carcinoma. *Journal of hepatology*, 41(5), pp.864-880
- Shen, J., Stass, S.A. and Jiang, F., 2013. MicroRNAs as potential biomarkers in human solid tumors. *Cancer Lett*, 329(2): 125–136. Available at: <http://doi.org/10.1016/j.canlet.2012.11.001>.
- Shi, Bao-Min, et al. 2017. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma." *World journal of gastroenterology*. 23.20 : 3713.
- Song, D., Ren, Y. and Li, M., 2020. Bioinformatics Analysis IdentifiesThrombospondin-1 and its related micro RNAs as biomarkers for Hepatocellular carcinoma.
- Tang, B., Lei, B., Qi, G., Liang, X., Tang, F., Yuan, S., & He, S. 2016. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. *Journal of Experimental & Clinical Cancer Research*, 35(1), 93.
- Tao, J., Jiang, L. and Chen, X., 2018. Roles of microRNA in liver cancer. *Liver Research*, 2(2), pp.61-72.
- Thulin, P., Rafter, I., Stockling, K., Tomkiewicz, C., Norjavaara, E., Aggerbeck, M., Hellmold, H., Ehrenborg, E., Andersson, U., Cotgreave, I. and Glinghammar, B., 2008. PPAR α regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. *Toxicology and applied pharmacology*, 231(1), pp.1-9.

- Tsang, H. F., Xue, V. W., Koh, S. P., Chiu, Y. M., Ng, L. P. W., & Wong, S. C. C. 2017. NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics. *Expert review of molecular diagnostics*. 17(1):95-103.
- Vander Ark, A., Cao, J. and Li, X., 2018. TGF- β receptors: In and beyond TGF- β signaling. *Cellular signalling*, 52, pp.112-120.
- Vasuri, F., Visani, M., Acquaviva, G., Brand, T., Fiorentino, M., Pession, A., Tallini, G., D'Errico, A. and de Biase, D., 2018. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. *World journal of gastroenterology*, 24(25), p.2647.
- Vrba, L., Muñoz-Rodríguez, J.L., Stampfer, M.R. and Futscher, B.W., 2013. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. *PloS one*, 8(1), p.e54398.
- Wang, G., Dong, F., Xu, Z., Sharma, S., Hu, X., Chen, D., Zhang, L., Zhang, J. and Dong, Q., 2017. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma. *BMC cancer*, 17(1), pp.1-11.
- Wang, H., Lu, Z., & Zhao, X. (2019). Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. *Journal of hematology & oncology*, 12(1), 1-21.
- Wang, H., Wang, P., Xu, M., Song, X., Wu, H., Evert, M., Calvisi, D.F., Zeng, Y. and Chen, X., 2021. Distinct functions of transforming growth factor- β signaling in c-MYC driven hepatocellular carcinoma initiation and progression. *Cell death & disease*, 12(2), pp.1-16.
- Wang J, Zhang KY, Liu SM, Sen S. 2014. Tumor-associated circulating microRNAs as biomarkers of cancer. *Molecules*. 1912–38.
- Wang, X. and Wang, Q. 2018. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. *Canadian Journal of Gastroenterology and Hepatology*, vol. 2018:(1–8). doi: 10.1155/2018/9049252.
- Wuchty S, Arjona D, Bozdag S, Bauer PO. Involvement of microRNA families in cancer. *Nucleic Acids Res*. 2012;40(17):8219–26.

- Xu, X., Tao, Y., Shan, L., Chen, R., Jiang, H., Qian, Z. & Yu, Y. 2018. The role of MicroRNAs in hepatocellular carcinoma. *Journal of Cancer*. Vol-9 (19) : 3557.
- Yang, F. 2011. Modulation of the Unfolded Protein Response Is The Core of Micro-RNA-122-involved Sensitivity to Chemotherapy in Hepatocellular Carcinoma. *Neoplasia* 13, 590-600.
- Zacharakis, G., Aleid, A. and Aldossari, K.K., 2018. New and old biomarkers of hepatocellular carcinoma. *Hepatoma Research*, 4:65. <http://dx.doi.org/10.20517/2394-5079.2018.76>.
- Zheng, Li., Leung, Eric., Lee, Nelson., Grace, Lui., Ka-Fai To., Raphael, C, Y, Chan., Margaret. 2020. Differential MicroRNA Expression in Human Macrophages with Mycobacterium tuberculosis Infection of Beijing/W and Non-Beijing/W Strain Types. *PLoS ONE*, 10(6): e0126018.
- Zhong, X., Huang, M., Kim, H, G., Yang, Z., Kushan, C., Wenjie, C., Romil, S., Robert, F, S., Suthat, L., and Charlie, D. 2020. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells. *Cellular and Molecular Gastroenterology and Hepatology*, Vol. 10 (2): 342-364.
- Zulfikar, M. S., & Kurniawaty, E. 2017. DNA Plasma sebagai Biomarker Potensial Kanker Payudara. *Jurnal Medula*, 7(5), 122-126.